ResMed is redoubling efforts to increase resupply with plans to make Snap, a software platform that monitors orders, ...

“That’s a marathon too, it’s a steady build over the next one, three, five quarters, the next one, three, five years.’’ ...

ResMed posted robust revenue and earnings growth but faces operational cost pressure due to rising expenses.

ResMed ( ASX: RMD) shares opened 8% higher as the market opened on Friday after the company reported a better-than-expected ...

Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 millionNote: A webcast of ...

ResMed beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep ...

On Thursday, ResMed Inc (NYSE:RMD) reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus ...

ResMed Inc (RMD) reports robust revenue growth and increased profitability, while navigating freight cost pressures and ...

There's plenty more upside, this fund says. The post Why this fundie is backing ResMed shares in FY25 appeared first on The ...

Chief executive Mick Farrell says the company has only scratched the service in global demand for sleeping disorder devices.

Wilsons analyst Shane Storey maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – ...

Shares in narrow-moat ResMed RMD remain undervalued following a solid first-quarter fiscal 2025. Underlying earnings before ...